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          安  室  朝  三
CLINICAL AND EXPERIIMENTAL STUDY ON INTRAVESICAL
    INSTILLAT工ON THERAPY OF ANTICANCER AGENTS
                ・ FOR BLADDER CANCER
                  Chozo YAsuMuRo
Fr・剃ん6 D吻吻Z副ヴUr・1・gy， Sch・・1げM麟6珈，κ・ゐ6σ加・rs吻
              （D｛γ伽・：Pγρプ，ノ．lshigami＞
   Intravesical instillation therapy of Mitomycin C （MMC） was attempted in 79 cases with
the aim of prophylaxis against recurrence of bladder cancer after surgery． 20 ml saline
solution containing 10 mg MMC was instilled into the bladder and retained for 2 hours once
every week for a total of IO instillation． The tumor free－rate of this treatment was 75．99
after 1 year， 69．5％ after 2 years and 63．6％o after 5 years， and the tumor－free rate of 32
cases witho’ut ehemoprophylaxis was 60．7％ after 1 year， 57％ after 2 years and 47．4％ after 5
years． The shape，’ multi’垂撃奄bi y ’and pathological grewth pattern of the cancer was clinica－
lly of ｛Chigh risk” r一 ecurrence． On the basis of Dur observations， this prophylactic instillation
therapy with MiMC is concluded to be useful for preventing the recurrence of bladder cancer
after removal．
   Transport of anticancer agents （FT－207， BLM， MMC）through the rabbit’s vesical mucesa
and the effect of dimethylsulfoxide （DMSO）， urokinase and hyaluronidase combined with
anticancer to permeability were studied． The vesical mucosa was placed tightly between two
syringes and transportion of anticancer material from one chamber to the other was inve－
stigated． ln decreasing order， 11．1％ of FT－207， 8．2％ of BLM， and 2．7％ of MMC，’were
transported within 4 hours． The permeability was not influenced by combination with uro－
kinase or DiMSQ，／ but increased with hyaluronidase． The preveqtion of recurrence of blad－
der cancer was attempted in 13 cases by means of combined intravesical instillation of MMC
and hyaluronidase． No recurrence was found for the postoperative 6ey14 month period and
slight miction pain was found in 2 out of 13 cases receiving the combined instillation therapy，
Ihave concluded that this treatment is safe and useful for preventing the recurrence of
bladder cancer． ’
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61例，high stageが8例である． high stageのも
のは，すべてpartial cystectomy後の再発予防とし
て本療法がおこなわれたため，対象に含まれている．
治療法別分類では，Partial cystectomy 29例， simPle
tumorectomy l5例， TUR 35例である．
 2）投与方法
Table 1． Recurrence rate of the bladder tumors after surgical treatment
Postoperative therapyNo． Pts        Recurrence rateNo． recurrence．              （％）
MMC
        MMC十Thio－tepa
        MMC十Cytrabine
  lntravesical        ADMA  instillation
        Carbequone


































Table 2． Postoperative intravesical instillation therapy with MMC
No． No．
Pt＄ RecurrenceO－1yrs
   Tumor free rate （％）























 ）20m 250．5一く2cm         34
 〈O．5cm 20Solitary tumor 59
MuStiple tumor 20
Go”G2 MG， 20PT， 一PT． 61
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       む ロロくレ サむ ロゆのコつ
       non－instiiiateCl group
         （32case5）
  O  i 2’ 3  4  5  6  7  8  9yrs・
Fig． 1． Tumor free rate of the bladder
    tumors aft’er intravesical instil－
    lation of MMC



















例，Grade 3（high grade）は20例， Gradeの不明
な症例は5例であった．10w gradeとhigh grade
の非再発率には推計学的有意差は認められなかった























  non－papillary tumor
   ｛13 cases）
  O ii3466789yrs．
Fig． 3． Tumor free rate of the bladder
    tumorsi according to shape （P〈
    O．05）
（％）
Fig． 4．Tumor free rate of the bladder




”，． IK primary case
X． V ’ （70 eases）t’t’
 ち
 V一炉・・o・・一〇・…o…一◎’．騨D。。●つ一一’o        recurrent case
         （9 cases）
  Oii34S6789yrs・Fig． 2． Tumor free rate of the bladder
    tumors according to previous
















  O  i 2’ 3 4  5  6  ？ 8  9yrs．
Fig． 5． Tumor free rate of the bladder
    tumors according to multiplicity






















































   噂、
ed．e grade O．v2 （M．cases）
   （low grade）
b一一〇grade 3 〈20 cases）
   （high grade）
  Oi 2’ 3456789yrs．
Fig． 6． Tumor free rate of the bladder
    tumors according to histopatho－












 ts－di partlaJ cystectomy
    （29 eases）
 H tran＄urethral reseetion
    （35 cases）
 o．一一〇 sjmple tumorectomy
    （15 cases＞
  Oi 2’ 34S6789yrs．
Fig． 7’ Tumor free rate of the bladder
    tumors according to the method










         P       P
Fig． 8． Diagram of circulation system for trans－
    port of anticancer agents through the
    vesical mucosa of rabbit． Component＄
    are： M． vesical mucosa． CA． contained
    Hanks’ solution and anticancer agent．
    CB． Hanks’ solution． P． Pump







































Fig． 9．Transport of MMC． BLM and FT－207 through
the vesical mucosa








   1 MMC： E． coli B
          （測定域 O．002 mcg／ml）
   E BLM： Bacillus subtilis PCI－219
          （測定域0・05mcg／ml）
   M FT－207： Staphylococcus aureus 209 P
          （測定域0。02mcg〆ml）
 2）成 績








UK（6000．u）， H Dase（300 u）をそれぞれ添加した
時のMMCのCBへの透過濃度は， DMSO添加時
1時間3．71mcg／ml，4時間7．58 mcg／m1， UK添加
時1時間2．97mcg／ml，4時間8．16 mcg／ml， H Dase
添加時1時間3．17mcg／m1，4時間7．38 mcg／mlとな
る．MMc単独の1時間3．44 mcg／ml，4時聞6．86
mcg／mlと比較するとDMso， uK， H Dase添加
した時のMMCの粘膜透過に差は認められなかった
（Fig． 10）．
 c）BLM l25 mcg／ml溶解液にDMSO（50％）
UKI（6000 u）， HDase（300 ul）をそれぞれ併用した
時のCBのBLM濃度は，．4時間値でBLM単独
10．25mcg／m1に対し， DMSO併用時4．83 mcg／ml，










にHDase 300 u， HDas¢3000 uを併用した場合の
FT－207の粘膜透過は， HDase 300 u濃度時は単独
安室：膀胱腫瘍・抗癌剤注入療法
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Fig． 10，Transport of MMC combined with DMSO，
 uroki’nase， and hyaluronidase through the
 vesical mucosa
  BLM 125 mcg／m2．  ◎一一r’o BLM
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BLM十HDase

















Fig． 11． Trahsport of BLM combined with DMSO，
      urokinase， and hyaluronidase through ’the
      vesical mucosa
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FT－207   （mcg／nd）
FT－207十DMSO
   （mcg／nd）
FT－207十UK
   （mcg／me）
FT－207十HDase
















Fig． 12． Transport of FT－207 combined with DMSO，





 f）MMC 250 mcg／m1単独と，同濃度のMMG
にHDase 300 u，3，000 uを併用した場合，4時間後
のMMCの透過は単独で6．86 mcg／ml， HDase 300
u併用時で7．38mcg／ml， HDase 3，000 u併用時で














DMSO， UK， HDaseを用いた実験では， HDase






















































Fig． 13．Transport of FT－207 combined with low









MMC十HDase     （ 300u）













Fig． 14．Transport of MMC cornbined with low and high
concentrated hyaluronidase
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Table 3．MMC concentration in blood and bladder carcinoma
tissues after instillation of MMC and hyaluronidase
Cases 1 2 3 4
Tumor 一『．C℃  T．C．C  T．C．C  T．C，C Histological grade
 Blood Concentration
         くコ ヨ 
認罫，，a，、。．L・m・・a岬・
       muscle
       supuficial
Tumor       middleTissues
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